The Effect of Exercise on Individuals With Parkinson's Disease
NCT00591344, Not applicable, Completed, University of Illinois Chicago; results first posted 2015-02-09
Trial 11
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effect of Exercise on Individuals With Parkinson's Disease | ClinicalTrials.gov |
| NCT number | NCT00591344 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 51 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Illinois Chicago | ClinicalTrials.gov |
| Conditions | Parkinson's Disease | ClinicalTrials.gov |
| Interventions | Progressive resistance training, Modified Fitness Counts | ClinicalTrials.gov |
| First posted | 2008-01-11 | ClinicalTrials.gov |
| Last updated | 2015-03-05 | ClinicalTrials.gov |
| Results first posted | 2015-02-09 | ClinicalTrials.gov |
Registered outcomes 35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Off Medication UPDRS Part III, Motor Subscale Score | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | UPDRS part III, is an observer rated clinical measure of motor signs of PD. It is used as a measure of severity of motor signs. We measured this at baseline, 6 , 18 and 24 months. This is a ordinal scale of 0-4 which has 27 items which measures slowness of movement (Bradykinesia), Tremor, Rigidity (muscle stiffness) and postural instabilty. The total value for UPDRS part III scale which ranges from 0 to 108, with a larger number indicating a higher level of impairment. | ClinicalTrials.gov |
| Secondary | On Medication UPDRS-III | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | UPDRS part III, is an observer rated clinical measure of motor signs of PD. It is used as a measure of severity of motor signs. We measured this at baseline, 6 , 18 and 24 months. This is a ordinal scale of 0-4 which has 27 items which measures slowness of movement (Bradykinesia), Tremor, Rigidity (muscle stiffness) and postural instabilty. The total value for the UPDRS part III scale which ranges from 0 to 108, with a larger number indicating a higher level of impairment. | ClinicalTrials.gov |
| Secondary | L-dopa equivalent-mg/Day | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | This was the equivalent amount of dopamine (mg/day) each subject was prescribed based upon all of their PD medications. | ClinicalTrials.gov |
| Secondary | Elbow Flexion Strength | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | This is the MVC for elbow flexion | ClinicalTrials.gov |
| Secondary | Ankle Plantar Flexion Strength | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | This is a measure of the MVC for ankle plantar flexion strength | ClinicalTrials.gov |
| Secondary | Elbow Extension Strength | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | This is a measure of the MVC for elbow extension | ClinicalTrials.gov |
| Secondary | Ankle Dorsiflexion Strength | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | This is a measure of the MVC for ankle dorsiflexion | ClinicalTrials.gov |
| Secondary | Percentage of Agonist EMG Signal Contained in the 0-5, 5-15, 15-30, and 35-50 Hz Frequency Bins During Isometric Contractions | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | This is a measure of the percentage of the EMG signal that is contained in different frequency bins during a MVC (elbow flexion/extension; ankle DF/PF), a 50% of MVC elbow fleixon contraction, and a 5 NM elbow flexion contraction. | ClinicalTrials.gov |
| Secondary | The Integral of the First Agonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | The Integral of the first agonist EMG signal from onset of the agonist EMG signal until peak velocity | ClinicalTrials.gov |
| Secondary | Magnitude of the First 30 ms of the Agonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | The integral of the first 30 msec of the agonist EMG. | ClinicalTrials.gov |
| Secondary | Magnitude of the Antagonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | the area under the rectified antagonist signal form agonist EMG onset until the end of movement. This reflects the amount of antagonist activation during movement. | ClinicalTrials.gov |
| Secondary | Magnitude of the Agonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | Magnitude of the agonist burst reflects the amount of agonist activation during movement. | ClinicalTrials.gov |
| Secondary | Duration of First Agonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | Time in (ms) for the duration of the first agonist burst during a 72 degree elbow flexion movement and also the percentage of agonist EMG bursts until peak velocity | ClinicalTrials.gov |
| Secondary | Number of Agonist Bursts | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | This is the number of agonist bursts prior to peak velocity. | ClinicalTrials.gov |
| Secondary | Co-contraction During Limb Acceleration | Obtained during initial evaluation & then every 6 six months to end of 2-yr training period | the amount of agonist and antagonist activity present during limb acceleration. | ClinicalTrials.gov |
| Secondary | Qant | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | The integral of the antagonist EMG signal from the onset of the agonist EMG to the end of the movement | ClinicalTrials.gov |
| Secondary | Time to Peak Velocity | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | Time of the onset of the movement to peak velocity. | ClinicalTrials.gov |
| Secondary | Peak Movement Velocity | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | This is how fast an individual can perform a 72 degree elbow flexion movement | ClinicalTrials.gov |
| Secondary | Relaxation Time | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | Time for a subject to passively relax their muscle after performing and isometric contraction to 50% of their MVC | ClinicalTrials.gov |
| Secondary | Rise Time | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | This is the time is takes for an individual to go for rest to a 50% of a MVC contraction as fast as possible. | ClinicalTrials.gov |
Outcomes 35
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|---|---|---|---|---|---|
| PRIMARY | Off Medication UPDRS Part III, Motor Subscale Score | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | units on a scale | MEAN | ClinicalTrials.gov | |
| SECONDARY | On Medication UPDRS-III | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | units on a scale | MEAN | ClinicalTrials.gov | |
| SECONDARY | L-dopa equivalent-mg/Day | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | mg/day | MEAN | ClinicalTrials.gov | |
| SECONDARY | Elbow Flexion Strength | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Ankle Plantar Flexion Strength | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Elbow Extension Strength | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Ankle Dorsiflexion Strength | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Percentage of Agonist EMG Signal Contained in the 0-5, 5-15, 15-30, and 35-50 Hz Frequency Bins During Isometric Contractions | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | The Integral of the First Agonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Magnitude of the First 30 ms of the Agonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Magnitude of the Antagonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Magnitude of the Agonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Duration of First Agonist Burst | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Number of Agonist Bursts | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Co-contraction During Limb Acceleration | Obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Qant | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Time to Peak Velocity | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Peak Movement Velocity | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Relaxation Time | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov | |||
| SECONDARY | Rise Time | obtained during initial evaluation & then every 6 six months to end of 2-yr training period | ClinicalTrials.gov |
Results by group 30
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|---|---|---|---|---|---|
| Off Medication UPDRS Part III, Motor Subscale Score | Modified Fitness Counts | baseline | 34.7 | Standard Deviation 11.5 | units on a scale | ClinicalTrials.gov |
| Off Medication UPDRS Part III, Motor Subscale Score | Progressive Resistance Exercise | baseline | 34.5 | Standard Deviation 11.9 | units on a scale | ClinicalTrials.gov |
| Off Medication UPDRS Part III, Motor Subscale Score | Modified Fitness Counts | 6 month | 29.3 | Standard Deviation 12.2 | units on a scale | ClinicalTrials.gov |
| Off Medication UPDRS Part III, Motor Subscale Score | Progressive Resistance Exercise | 6 month | 28.0 | Standard Deviation 10.9 | units on a scale | ClinicalTrials.gov |
| Off Medication UPDRS Part III, Motor Subscale Score | Modified Fitness Counts | 12 month | 32.8 | Standard Deviation 12.4 | units on a scale | ClinicalTrials.gov |
| Off Medication UPDRS Part III, Motor Subscale Score | Progressive Resistance Exercise | 12 month | 28.4 | Standard Deviation 10.8 | units on a scale | ClinicalTrials.gov |
| Off Medication UPDRS Part III, Motor Subscale Score | Modified Fitness Counts | 18 month | 32.8 | Standard Deviation 12.3 | units on a scale | ClinicalTrials.gov |
| Off Medication UPDRS Part III, Motor Subscale Score | Progressive Resistance Exercise | 18 month | 28.6 | Standard Deviation 9.4 | units on a scale | ClinicalTrials.gov |
| Off Medication UPDRS Part III, Motor Subscale Score | Modified Fitness Counts | 24 month | 34.0 | Standard Deviation 12.6 | units on a scale | ClinicalTrials.gov |
| Off Medication UPDRS Part III, Motor Subscale Score | Progressive Resistance Exercise | 24 month | 25.8 | Standard Deviation 10.6 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Modified Fitness Counts | Baseline | 20.9 | Standard Deviation 8.0 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Progressive Resistance Exercise | Baseline | 21.6 | Standard Deviation 10.1 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Modified Fitness Counts | 6 month | 17.7 | Standard Deviation 8.6 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Progressive Resistance Exercise | 6 month | 19.1 | Standard Deviation 9.0 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Modified Fitness Counts | 12 month | 19.1 | Standard Deviation 8.4 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Progressive Resistance Exercise | 12 month | 19.4 | Standard Deviation 8.5 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Modified Fitness Counts | 18 month | 18.1 | Standard Deviation 9.7 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Progressive Resistance Exercise | 18 month | 18.4 | Standard Deviation 6.5 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Modified Fitness Counts | 24 month | 19.3 | Standard Deviation 9.7 | units on a scale | ClinicalTrials.gov |
| On Medication UPDRS-III | Progressive Resistance Exercise | 24 month | 17.9 | Standard Deviation 8.7 | units on a scale | ClinicalTrials.gov |
Participant flow 8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|---|---|---|---|---|
| Overall Study | STARTED | 1 Progressive Resistance Training | 25 | ClinicalTrials.gov | |
| Overall Study | STARTED | 2 Modified Fitness Counts | 26 | ClinicalTrials.gov | |
| Overall Study | Completed the 6 Month Test | 1 Progressive Resistance Training | 24 | ClinicalTrials.gov | |
| Overall Study | Completed the 6 Month Test | 2 Modified Fitness Counts | 24 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | 1 Progressive Resistance Training | 20 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | 2 Modified Fitness Counts | 18 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | 1 Progressive Resistance Training | 5 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | 2 Modified Fitness Counts | 8 | ClinicalTrials.gov |
Adverse events 26
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|---|---|---|---|---|---|---|
| other | Wrist pain | Musculoskeletal and connective tissue disorders | 1 Progressive Resistance Training | 0 | 25 | 0 | ClinicalTrials.gov |
| other | Wrist pain | Musculoskeletal and connective tissue disorders | 2 Modified Fitness Counts | 1 | 26 | 1 | ClinicalTrials.gov |
| serious | Passed away | Injury, poisoning and procedural complications | 1 Progressive Resistance Training | 0 | 25 | 0 | ClinicalTrials.gov |
| serious | Passed away | Injury, poisoning and procedural complications | 2 Modified Fitness Counts | 1 | 26 | 1 | ClinicalTrials.gov |
| serious | DBS surgery | Nervous system disorders | 1 Progressive Resistance Training | 2 | 25 | 2 | ClinicalTrials.gov |
| serious | DBS surgery | Nervous system disorders | 2 Modified Fitness Counts | 2 | 26 | 2 | ClinicalTrials.gov |
| serious | ALS | Musculoskeletal and connective tissue disorders | 1 Progressive Resistance Training | 0 | 25 | 0 | ClinicalTrials.gov |
| serious | ALS | Musculoskeletal and connective tissue disorders | 2 Modified Fitness Counts | 1 | 26 | 1 | ClinicalTrials.gov |
| serious | Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1 Progressive Resistance Training | 0 | 25 | 0 | ClinicalTrials.gov |
| serious | Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 2 Modified Fitness Counts | 1 | 26 | 1 | ClinicalTrials.gov |
| serious | Bowel obstruction | Gastrointestinal disorders | 1 Progressive Resistance Training | 1 | 25 | 1 | ClinicalTrials.gov |
| serious | Bowel obstruction | Gastrointestinal disorders | 2 Modified Fitness Counts | 0 | 26 | 0 | ClinicalTrials.gov |
| serious | Elbow pain | Musculoskeletal and connective tissue disorders | 1 Progressive Resistance Training | 1 | 25 | 1 | ClinicalTrials.gov |
| serious | Elbow pain | Musculoskeletal and connective tissue disorders | 2 Modified Fitness Counts | 0 | 26 | 0 | ClinicalTrials.gov |
| serious | Back surgery | Musculoskeletal and connective tissue disorders | 1 Progressive Resistance Training | 0 | 25 | 0 | ClinicalTrials.gov |
| serious | Back surgery | Musculoskeletal and connective tissue disorders | 2 Modified Fitness Counts | 1 | 26 | 1 | ClinicalTrials.gov |
| serious | Bilateral hip replacement | Musculoskeletal and connective tissue disorders | 1 Progressive Resistance Training | 1 | 25 | 1 | ClinicalTrials.gov |
| serious | Bilateral hip replacement | Musculoskeletal and connective tissue disorders | 2 Modified Fitness Counts | 0 | 26 | 0 | ClinicalTrials.gov |
| serious | unilateral knee replacement | Musculoskeletal and connective tissue disorders | 1 Progressive Resistance Training | 1 | 25 | 2 | ClinicalTrials.gov |
| serious | unilateral knee replacement | Musculoskeletal and connective tissue disorders | 2 Modified Fitness Counts | 0 | 26 | 0 | ClinicalTrials.gov |
Adverse event totals 6
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|---|---|---|---|
| Total, all-cause mortality | 1 Progressive Resistance Training | ClinicalTrials.gov | ||
| Total, all-cause mortality | 2 Modified Fitness Counts | ClinicalTrials.gov | ||
| Total, other adverse events | 1 Progressive Resistance Training | 0 | 25 | ClinicalTrials.gov |
| Total, other adverse events | 2 Modified Fitness Counts | 1 | 26 | ClinicalTrials.gov |
| Total, serious adverse events | 1 Progressive Resistance Training | 8 | 25 | ClinicalTrials.gov |
| Total, serious adverse events | 2 Modified Fitness Counts | 6 | 26 | ClinicalTrials.gov |
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| R01NS028127 | Motor Deficits - Experimental and Clinical Correlates | CORCOS, DANIEL M. | UNIVERSITY OF ILLINOIS AT CHICAGO | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE | 1993 to 2011 | NIH RePORTER |
Trial comparisons 1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| 1 Progressive Resistance Training vs 2 Modified Fitness Counts: serious adverse events | Trial comparisons |
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)